Operating
Gain (Loss) on Sale of Assets and Asset Impairment Charges
Over 4 years (FY 2021 to FY 2025), Gain (Loss) on Sale of Assets and Asset Impairment Charges shows a downward trend with a -100.0% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2013
Last reportedQ4 2025Feb 11, 2026
Metric ID:
operating_gain_loss_on_sales_of_assets_and_asset_impairm_2fb394Historical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $295.97M | -$8.4M | $71.19M | $0 | $0 |
| YoY Change | — | -102.8% | +947.5% | -100.0% | — |
Range-$8.4M – $295.97M
CAGR-100.0%
Avg YoY Growth+248.2%
Median YoY Growth-100.0%
Gain (Loss) on Sale of Assets and Asset Impairment Charges at Other Companies
Frequently Asked Questions
- What is Albemarle's gain (loss) on sale of assets and asset impairment charges?
- Albemarle (ALB) reported gain (loss) on sale of assets and asset impairment charges of $0 in Q4 2025.
- What is the long-term trend for Albemarle's gain (loss) on sale of assets and asset impairment charges?
- Over 4 years (2021 to 2025), Albemarle's gain (loss) on sale of assets and asset impairment charges has grown at a -100.0% compound annual growth rate (CAGR), from $295.97M to $0.